A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06212999)
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Who can join: Review the eligibility criteria below.
Location: Investigative Site US303 — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (165 Sites)
Showing the first 25 of 165 sites.
- Investigative Site US303 — Phoenix, Arizona
- Investigative Site US240 — Scottsdale, Arizona
- Investigative Site US307 — Fort Smith, Arkansas
- Investigative Site US214 — Rogers, Arkansas
- Investigative Site US315 — Laguna Niguel, California
- Investigative Site US223 — Los Angeles, California
- Investigative Site US222 — Oakland, California
- Investigative Site US226 — San Diego, California
- Investigative Site US309 — Clearwater, Florida
- Investigative Site US317 — Hialeah, Florida
- Investigative Site US306 — Hollywood, Florida
- Investigative Site US320 — Hollywood, Florida
- Investigative Site US316 — Maitland, Florida
- Investigative Site US227 — Margate, Florida
- Investigative Site US204 — Miami, Florida
- Investigative Site US236 — Miami, Florida
- Investigative Site US321 — North Miami Beach, Florida
- Investigative Site US200 — Ocala, Florida
- Investigative Site US228 — Tampa, Florida
- Investigative Site US201 — Tampa, Florida
- Investigative Site US311 — Marietta, Georgia
- Investigative Site US220 — West Dundee, Illinois
- Investigative Site US206 — Indianapolis, Indiana
- Investigative Site US337 — Indianapolis, Indiana
- Investigative Site US341 — Bowling Green, Kentucky
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hidradenitis Suppurativa (HS)
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense — Phoenix, Arizona
- Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa — Missouri City, Texas
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) — Irvine, California
- A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa — Worcester, Massachusetts
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa — Chapel Hill, North Carolina
Explore by condition: All Hidradenitis Suppurativa (HS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.